Stock Market Today: Dow Up On GDP; Amgen Jumps To New Highs, As Abbott Gets Crushed (Live Coverage)
Amgen's Surge and Abbott's Decline Highlight Divergent Healthcare Fortunes
Stronger-than-expected GDP data bolstered investor confidence, reinforcing the 'soft landing' narrative despite high interest rates. This positive economic backdrop allowed sector-specific stories, particularly in healthcare, to take center stage.
Upcoming PCE inflation data will be crucial for determining if the current economic momentum can be sustained.
Key Takeaways
- 1Stronger-than-expected GDP growth data bolstered investor confidence in the U.S. economy's resilience, driving gains in the Dow Jones Industrial Average.
- 2Amgen (AMGN) hit record highs as the market increasingly prices in the potential of its metabolic and weight-loss drug pipeline to capture significant market share.
- 3Abbott Laboratories (ABT) experienced a sharp sell-off, underperforming the broader healthcare sector despite the favorable macroeconomic backdrop.
- 4The market reaction illustrates a significant performance gap within the healthcare sector, favoring biotechnology innovators over medical device manufacturers.
U.S. equity markets showed resilience today as the Dow Jones Industrial Average rose following a stronger-than-expected GDP print, signaling that the 'soft landing' narrative remains intact despite elevated interest rates. Investor focus shifted toward a divergent healthcare sector. Amgen (AMGN) powered to new all-time highs, buoyed by positive data regarding its obesity drug pipeline and favorable cardiovascular outcomes, positioning it as a serious contender against incumbent leaders like Novo Nordisk and Eli Lilly. Conversely, Abbott Laboratories (ABT) faced significant selling pressure, likely due to concerns regarding organic growth pacing in its medical device segment or lingering litigation overhangs. This divergence underscores a broader market trend where investors are beginning to pivot away from broad tech-heavy indices toward selective blue-chip names with defensive moats or idiosyncratic catalysts. For sophisticated investors, the focus remains on the 'higher-for-longer' rate environment's impact on balance sheets, though current GDP data suggests consumer spending remains robust enough to support earnings growth in cyclical sectors. Watch for upcoming PCE inflation data, which will dictate if this GDP-driven momentum can be sustained.